Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab

Iwata, Daiju; Namba, Kenichi; Mizuuchi, Kazuomi; Kase, Satoru; Takemoto, Yuko; Ohno, Shigeaki; Ishida, Susumu

doi:10.1007/s00417-011-1908-1

Cited by 20 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pink et al have proposed that the development of ANA in psoriatic patients treated with anti‐TNFα may predict treatment failure, but Golberg et al have proposed alternative explanations, as multiple therapies received by these patients could increase the chance of development of ANA [57, 58]. Finally, Iwata et al have showed a correlation between elevated ANA titers and decreased therapeutic efficacy in the treatment of Behçet disease with infliximab [59].…”

Section: Dile Due To Anti‐tnfα Agentsmentioning

confidence: 99%

Drug‐induced lupus erythematosus with emphasis on skin manifestations and the role of anti‐TNFα agents

Vedove

Simon

Girolomoni

2012

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Drug-induced lupus erythematosus (DILE) is a lupus-like syndrome temporally related to continuous drug exposure which resolves upon drug discontinuation. There are currently no standard diagnostic criteria for DILE. Findings include skin manifestations, arthritis, serositis, anti-nuclear and anti-histone antibodies positivity. Similarly to idiopathic lupus erythematosus, DILE can be divided into systemic (SLE), subacute cutaneous (SCLE) and chronic cutaneous lupus (CCLE). Systemic DILE presents as a milder version of idiopathic SLE, and the drugs most frequently implicated are hydralazine, procainamide and quinidine. Anti-TNFα therapies are the latest class of medications found to be associated, although rarely, with a “lupus-like” syndrome, which is however clinically distinct from classical DILE. Drug-induced SCLE is the most common form of DILE. It is very similar to idiopathic SCLE in terms of clinical and serologic characteristics. The most commonly implicated drugs are antihypertensive drugs and terbinafine, but in recent years also proton pump inhibitors and chemotherapeutic agents have been associated. Drug-induced CCLE is very rare and usually caused by fluorouracil agents and NSAIDS, but some cases have induced by pantoprazole and anti-TNFα agents.

show abstract

Section: Dile Due To Anti‐tnfα Agentsmentioning

confidence: 99%

Drug‐induced lupus erythematosus with emphasis on skin manifestations and the role of anti‐TNFα agents

Vedove

Simon

Girolomoni

2012

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…53 Anti-TNFα may lead to apoptotic cell death and the release of autoantigens that induce antiDNA antibodies in susceptible patients. 54,55 Downregulation of TNFα may be associated with autoantibody production due to the upregulation of IL-10, which activates autoreactive B cells. 53 Local complications at the site of drug administration have been frequently reported.…”

Section: Anti-tnfα Agents and Hla-b27-associated Uveitismentioning

confidence: 99%

Biologic Therapy for HLA-B27-associated Ocular Disorders

Gueudry

Thorne

Bansie

et al. 2016

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

The treatment of articular and extra-articular manifestations associated with HLA-B27 has undergone dramatic changes over the past two decades, mainly as a consequence of the introduction of biologic agents and in particular anti-tumor necrosis factor α (anti-TNFα) agents. Uveitis is known to be the most frequent extra-articular feature in HLA-B27-associated spondyloarthritides. Topical corticosteroids and cycloplegic agents remain the cornerstones of treatment. However, biologic therapy may be effective in the management of refractory or recurrent forms of uveitis. This review gives an update on the management of HLA-B27-associated ocular disorders with biologics, including anti-TNFα agents and non-anti-TNFα biologic modifier drugs. There is an emerging role for newer biologics targeting interleukin-12/23 and interleukin-17 for the treatment of spondyloarthritides but data on their efficacy on anterior uveitis are sparse.

show abstract

“…One of the considerations in giving infliximab is that it can potentially induce antinuclear antibody (ANA) and anti-double stranded DNA on long term therapy. [3031] Early monitoring and optimizing dose regimens can be useful in patients on long term Infliximab therapy. It has been shown to be superior to etanercept in preventing relapses and remission in various trials.…”

Section: Biologics In Use For Uveitismentioning

confidence: 99%

Cytokines and Biologics in non-infectious autoimmune uveitis: Bench to Bedside

Agrawal

Iyer

Connolly

et al. 2014

Indian J Ophthalmol

Self Cite

View full text Add to dashboard Cite

Intraocular inflammatory eye disease is one of the important causes of ocular morbidity. Even though the prevalence of uveitis is less common in relation to diabetic retinopathy, glaucoma or age related macular degeneration, the complexity and heterogeneity of the disease makes it more unique. Putative uveitogenic retinal antigens incite innate immunity by the process of antigen mimicry and have been shown to be associated in patients with intraocular inflammatory disease by numerous experimental studies. Laboratory diagnostic tools to aid the etiologic association in intraocular inflammatory disease have evolved over the last two decades and we are entering into an era of molecular diagnostic tests. Sophisticated novel technologies such as multiplex bead assays to assess biological signatures have revolutionized the management of complex refractory uveitis. Nevertheless, there is still a long way to go to establish the causal relationship between these biomarkers and specific uveitic entities. Experimental studies have shown the supreme role of infliximab in the management of Behcet's disease. Despite significant experimental and case control studies, the deficiency of randomized clinical trials using these biologic agents has handicapped us in exploring them as a front line therapy in severe refractory uveitis. Studies still need to answer the safety of these potentially life threatening drugs in a selected group of patients and determine when to commence and for how long the treatment has to be given. This review article covers some basic concepts of cytokines in uveitis and their potential application for therapy in refractory uveitis.

show abstract

Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab

Abstract: Background: Infliximab, an anti-TNF- monoclonal antibody, administered to Behçet's disease (BD) patients in

Cited by 20 publications

References 46 publications

Drug‐induced lupus erythematosus with emphasis on skin manifestations and the role of anti‐TNFα agents

Drug‐induced lupus erythematosus with emphasis on skin manifestations and the role of anti‐TNFα agents

Biologic Therapy for HLA-B27-associated Ocular Disorders

Cytokines and Biologics in non-infectious autoimmune uveitis: Bench to Bedside

Contact Info

Product

Resources

About